Screener
AbCellera Biologics Inc. ABCL Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -340.3%+507pp | -267.6%+1,128pp | -289%+803pp | -739.7%+195pp | -847.6%-32.9pp | |
| Net margin | -248.8%+255pp | -181.7%+544pp | -194.9%+370pp | -486%+47.3pp | -503.9%-40.1pp | |
| Returns | ||||||
| Return on equity | -17.3%-1.7pp | -14.7%+0.9pp | -14.5%+0.3pp | -16.8%-1.3pp | -15.6%-2.3pp | |
| Return on invested capital | -23.5%+3.8pp | -22.5%+10.4pp | -22.3%+8.2pp | -26.2%+3.7pp | -27.3%-1.5pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 12.8×+1.7× | 14.1×+3.9× | 11.3×+1.5× | 10.1×+0.8× | 11.1×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | |
| Per Share | ||||||
| Book value per share | $2.93-13.1% | $3.10-9.9% | $3.24-9.8% | $3.23-11.8% | $3.37-10.7% | |
| Valuation | ||||||
| Market capitalization | $1.99B+62.2% | $1.06B+59.2% | $1.02B+18.3% | $1.5B+96.2% | $1.1B+26.2% | |
| Price / sales | 30.1×-7.3× | 13.4×-15.4× | 13.6×-16.4× | 42.6×+19.3× | 33.4×+7.1× | |
| Price / book | 2.2×+1.0× | 1.1×+0.5× | 1.1×+0.2× | 1.6×+0.8× | 1.1×+0.3× |
FAQ
- Where do AbCellera Biologics Inc.'s ratios come from?
- Every ratio is computed from AbCellera Biologics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
